Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment

The anaplastic lymphoma kinase (ALK) gene rearrangement is a driving mutation that underlies about 5-6% of non-small cell lung cancer (NSCLC) cases. Lung cancers that are ALK gene rearrangement-positive can be effectively treated with ALK inhibitors. However, the response of patients with rarer ALK...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Peng, Tang, Kangning, Hao, Yuqiu, Li, Wei, Lv, Xuejiao, Li, Dapeng, Jia, Yuxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914946/
https://www.ncbi.nlm.nih.gov/pubmed/35280798
http://dx.doi.org/10.3389/fonc.2022.762338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914946/
https://www.ncbi.nlm.nih.gov/pubmed/35280798
http://dx.doi.org/10.3389/fonc.2022.762338

Ejemplares similares